Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)
Sponsored by Vanda Pharmaceuticals
About this trial
Last updated 3 years ago
Study ID
VP-VLY-686-3102
Status
Completed
Type
Interventional
Phase
Phase 3
Placebo
Yes
Accepting
18 to 70 Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 5 years ago
What is this trial about?
This is a multi-center, randomized, double-blind, placebo-controlled study to be conducted in
the United States in subjects with atopic dermatitis.
What are the participation requirements?
Inclusion Criteria
- Male and non-pregnant, non-lactating female patients aged 18 - 70 years (inclusive);
- Diagnosed with atopic dermatitis;
- Suffering from chronic pruritus;
- Body Mass Index (BMI) of ≥18 and ≤40 kg/m2
Exclusion Criteria
- Chronic pruritus due to condition other than atopic dermatitis (AD);
- A positive test for drugs of abuse at the screening or evaluation visits;
- Exposure to any investigational medication in the past 60 days